US2024026051A1PendingUtilityA1
Cationic cyclic amine and amphipathic transfection reagents
Est. expiryFeb 26, 2035(~8.6 yrs left)· nominal 20-yr term from priority
C08F 226/06C07D 241/04C12N 15/87C07D 295/13C09D 139/04
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Cationic cyclic amine containing polymers and copolymers as well as novel lipids have been designed and synthesized for efficient delivery of nucleic acids to cells in biological systems, specifically for in vitro cell transfection research.
Claims
exact text as granted — not AI-modified1 - 4 . (canceled)
5 . A transfection reagent comprising an amphipathic compound having the structure:
wherein
m is 2, 3, 4, 5, or 6;
n is 0 or 1;
R 1 and R 2 are each a lipid group; and
R 3 and R 4 are each selected from the group consisting of:
(i) hydrogen,
(ii) —C(═O)—R 6 ,
(iii) an amino acid linked by an amide bond, or
(iv) 2-pyridyl,
wherein
k is 0, 1, 2, 3, or 4; and
R 6 is
6 . The transfection reagent of claim 5 , wherein said lipid group is a linear C 10 -C 20 alkyl, a branched C 10 -C 20 alkyl, a linear C 10 -C 20 alkenyl, a branched C 10 -C 20 alkenyl, or —C(═O)—R 5 ;
wherein each R 5 is a linear C 9 -C 19 alkyl, a branched C 9 -C 19 alkyl, a linear C 9 -C 19 alkenyl, or a branched C 9 -C 19 alkenyl.
7 . The transfection reagent of claim 6 , wherein each said lipid group is —C(═O)—R 5 .
8 . The transfection reagent of claim 7 , wherein said R 5 is said linear C 9 -Cig alkenyl, or said branched C 9 -C 19 alkenyl, wherein each said linear C 9 -C 19 alkenyl or said branched C 9 -C 19 alkenyl comprises 1, 2, or 3 double bonds.
9 . The transfection reagent of claim 6 , wherein each said lipid group is said linear C 10 -C 20 alkenyl, or said branched C 10 -C 20 alkenyl.
10 . The transfection reagent of claim 9 , wherein each said linear C 10 -C 20 alkenyl or said branched C 10 -C 20 alkenyl comprises 1, 2, or 3 double bonds.
11 . The transfection reagent of claim 10 , wherein each of said 1, 2, or 3 double bonds are cis-double bonds.
12 . The transfection reagent of claim 5 , wherein said R 3 and said R 4 are each hydrogen.
13 . The transfection reagent of claim 5 , wherein said R 3 and said R 4 are each —C(═O)—R 6 , wherein each said R 6 is
14 . The transfection reagent of claim 5 , wherein said R 3 and said R 4 are each an amino acid linked by an amide bond.
15 . The transfection reagent of claim 5 , wherein each said m is 3 or 4.
16 . The transfection reagent of claim 15 , wherein said n is 0.
17 . The transfection reagent of claim 16 , wherein said m is 4, said n is 0, said R 1 and said R 2 are each said linear C 10 -C 20 alkenyl, or said branched C 10 -C 20 alkenyl, and said R 3 and said R 4 are each hydrogen.
18 . The transfection reagent of claim 17 , comprising an amphipathic compound having the structure:
19 . A transfection reagent comprising said amphipathic compound of claim 5 , and a nucleic acid.
20 . A method of transfecting a nucleic acid into a cell, comprising mixing said amphipathic compound of claim 5 with said nucleic acid to produce a mixed solution, and contacting said cell with said mixed solution, thereby transfecting said nucleic acid into said cell.
21 . A transfection reagent, comprising an amphipathic compound having the structure:
22 . A transfection reagent comprising said amphipathic compound of claim 21 , and a nucleic acid.
23 . A method of transfecting a nucleic acid into a cell, comprising mixing said amphipathic compound of claim 21 with said nucleic acid to produce a mixed solution, and contacting said cell with said mixed solution, thereby transfecting said nucleic acid into said cell.Join the waitlist — get patent alerts
Track US2024026051A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.